Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2024-12-17 00:00:00 ET · period of report 2024-12-14 · accession 0001127602-24-029602 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-17 | 2024-12-14 | BCRX | Gayer Charles K | Chief Commercial Off | F - Tax | $7.53 | -8,251 | 300.1K | -3% | -$62.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-14 | F | D | 8,251 | $7.53 | 300,057 | D | — | — | (F1) Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person. |